Europe Traumatic Brain Injury Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
1.01 Billion
USD
1.60 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 1.01 Billion |
 시장 규모(예측 연도) |
USD 1.60 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
유럽 외상성 뇌 손상 치료 시장 세분화, 치료(수술, 응급 처치, 약물), 투여 경로(비경구, 경구 및 기타), 환자 연령(소아, 청소년, 노인), 성별(남녀), 손상 원인(낙상, 교통사고, 스포츠 및 기타), 최종 사용자(병원, 신경과 클리닉, 독립 약국 및 기타) - 2032년까지의 산업 동향 및 전망
외상성 뇌 손상 치료 시장 규모
- 유럽 외상성 뇌 손상 치료 시장은 2024년에 10억 1 천만 달러 규모로 평가되었으며 2032년까지 16억 달러 에 이를 것으로 예상됩니다 .
- 2025년부터 2032년까지의 예측 기간 동안 시장은 주로 외상성 뇌 손상(TBI) 발생률 증가에 따라 연평균 성장률 6.0%로 성장할 것으로 예상됩니다.
- 이러한 성장은 외상성 뇌 손상(TBI) 발생률 증가, TBI 치료에 최소 침습적 시술 도입 증가, 외상성 뇌 손상 치료 수요 증가와 같은 요인에 의해 촉진됩니다.
외상성 뇌 손상 치료 시장 분석
- 외상성 뇌 손상(TBI) 치료 시장은 TBI에 대한 인식 증가, 진단 기술의 발전, 사고 및 스포츠 관련 부상 발생률 증가로 인해 상당히 확대될 것으로 예상되며, 효과적인 치료 옵션과 재활 요법에 대한 수요가 증가하고 있습니다.
- 시장에서는 신경 보호제, 줄기 세포 치료, 첨단 재활 기술을 포함한 혁신적인 치료법이 급증하고 있으며, 이를 통해 회복 결과가 향상되고 TBI 환자의 치료 환경이 확대되고 있습니다.
- 독일은 첨단 의료 인프라와 의학 연구 개발에 대한 상당한 투자로 인해 유럽 외상성 뇌 손상(TBI) 치료 시장을 선도할 것으로 예상됩니다.
보고서 범위 및 외상성 뇌 손상 치료 시장 세분화
|
속성 |
외상성 뇌 손상 치료 시장 통찰력 |
|
다루는 세그먼트 |
|
|
포함 국가 |
유럽
|
|
주요 시장 참여자 |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Traumatic Brain Injury Treatment Market Trends
“Growing Adoption of Telemedicine in TBI Treatment”
- Telemedicine allows patients to receive remote consultations and rehabilitation services, improving access to specialized care for individuals in rural or underserved areas, thus facilitating timely intervention for TBI patients
- Utilizing telehealth reduces the costs associated with in-person visits, including travel expenses and lost productivity, making it a financially viable option for both patients and healthcare providers
- In March 2021, NCBI stated that Telehealth visits for patients with acquired brain injuries and their caregivers can ease the burden of transportation, improve compliance, and increase overall satisfaction. Management strategies are largely unaffected in the telehealth setting, and telerehab options have been found to be equal or superior to in-person therapy to treat many associated deficits
- Telemedicine platforms enable continuous monitoring and follow-up care, allowing healthcare professionals to track patient progress remotely, provide real-time feedback, and adjust treatment plans as necessary, ultimately enhancing patient outcomes in TBI management
Traumatic Brain Injury Treatment Market Dynamics
Driver
“Increasing Incidence of Traumatic Brain Injury (TBI)”
- As the number of cases continues to rise due to various contributing factors such as road accidents, sports-related injuries, and falls, particularly among the elderly population. Road traffic accidents remain one of the leading causes of TBI worldwide, with the growing number of vehicles on the road, reckless driving behaviours
- Sports-related injuries, particularly in contact sports like football, boxing, and rugby, have further fueled the surge in TBI cases, with increasing awareness of concussion-related complications prompting the need for advanced treatment solutions
For instance,
- In March 2025, as per the article published by ScienceDirect, there were 20.84 million incident cases and 37.93 million prevalent cases of Traumatic Brain Injury (TBI) Europely, leading to 5.48 million, Years Lived With Disability (YLDs). The rising burden of TBI increases the demand for advanced treatments, driving investments in diagnostics, neurosurgery, and rehabilitation, ultimately fueling the growth of the Europe TBI treatment market
- In October 2024, according to the data published by Centers for Disease Control and Prevention, In 2021, there were 69,473 TBI-related deaths, and in 2020, approximately 214,110 hospitalizations occurred. This equates to over 586 hospitalizations and 190 deaths per day, with individuals aged 75+ and males being the most affected. The rising burden of TBI necessitates advanced treatment solutions, driving growth in the Europe TBI treatment market
- Factors such as road accidents, sports injuries, and falls—especially among the elderly—contribute to increase in TBI. Growing awareness and demand for advanced treatments, including neurosurgery, drug therapies, and rehabilitation, are fuelling market expansion and technological advancements in TBI management
Opportunity
“Rising Personalized and Targeted Therapies in Traumatic Brain Injury (TBI)”
- TBI is a highly variable condition influenced by severity, location, and patient-specific factors, making traditional treatments less effective. Advances in biomarker discovery, neuroimaging, and computational modeling help identify distinct injury patterns, enabling more targeted therapies. Pharmacogenomics enhances drug selection and dosing, minimizing side effects while maximizing effectiveness. Personalized rehabilitation strategies, tailored to cognitive and motor impairments, further optimize recovery by aligning treatments with individual healing trajectories
For instance,
- In February 2022, as per NCBI, researchers have discovered genetic risk factors like APOE4 and BDNF Val66Met polymorphisms that impact TBI recovery. By focusing on these variations, personalized treatments can lower harmful biomarkers, enhance neuroprotection, and improve rehabilitation. This approach tailors’ therapies to individual needs, ultimately leading to better long-term functional outcomes for TBI patients
- In February 2024, article by MDPI TBI presents a significant opportunity to enhance patient outcomes. Advancements in biomarker discovery, pharmacogenomics, and neuroimaging enable precision treatments tailored to individual injury profiles. Emerging therapies, including neurostimulation and stem cell treatments, further expand possibilities for effective, patient-specific interventions in TBI management
- 개인 맞춤형 및 표적 치료는 개인의 유전적 및 분자적 특성에 맞춰 개입을 조정함으로써 외상성 뇌손상(TBI) 관리에 혁신적인 접근법을 제시합니다. 이러한 전략은 특정 바이오마커와 세포 과정에 초점을 맞춰 이차 손상을 줄이고 회복을 개선합니다. 개인 맞춤형 치료는 치료를 최적화함으로써 TBI 환자의 치료 결과를 향상시키고 장기적인 기능 회복을 촉진합니다.
제지/도전
“TBI 치료를 위한 혈액-뇌 장벽 극복의 어려움”
- 외상성 뇌손상(TBI) 치료의 중요한 과제 중 하나는 혈액-뇌 장벽(BBB)의 손상입니다. TBI 후 혈액-뇌 장벽(BBB)이 손상되어 유해 물질이 뇌로 유입될 수 있으며, 이는 손상을 악화시키고 회복을 저해할 수 있습니다. 이로 인해 치료제의 효과적인 전달이 어려워지고, 회복을 돕고 뇌 조직을 보호하기 위한 많은 치료의 성공률이 저하됩니다.
- 더욱이, 추가적인 손상을 유발하지 않고 혈액-뇌 장벽(BBB)의 온전성을 회복하는 것은 여전히 중요한 과제로 남아 있습니다. 추가적인 위험을 유발하지 않으면서 손상된 장벽을 우회할 수 있는 표적 전달 시스템 개발은 외상성 뇌손상(TBI) 치료 결과를 개선하는 데 필수적입니다.
예를 들어,
- 2022년 1월, Springer Nature Publishing Inc는 혈액-뇌 장벽(BBB)이 치료제의 뇌 전달을 제한한다고 보고했습니다. 손상 후 BBB가 손상되더라도 많은 약물, 특히 거대 분자는 여전히 BBB를 통과하는 데 어려움을 겪어 치료 효과를 제한하고 표적 치료를 복잡하게 만듭니다.
- 2024년 6월, Nature Reviews Neurology는 뇌혈관 뇌허혈 장애(BBB) 기능 장애가 외상성 뇌손상(TBI) 후 며칠에서 몇 년까지 지속될 수 있으며, 장기적인 신경학적 합병증을 유발할 수 있다고 보고했습니다. 이러한 기능 장애는 부종, 신경 염증, 신경망 변화와 연관되어 치료 전략을 복잡하게 만들고 인지 기능 장애, 우울증, 외상 후 간질로 이어지며, 효과적인 회복과 치료 접근법을 어렵게 만듭니다.
- 혈액-뇌 장벽(BBB) 손상은 외상성 뇌손상(TBI) 치료에 있어 심각한 과제로, 효과적인 치료 전달을 제한하고 뇌 손상을 악화시킵니다. 지속적인 BBB 기능 장애는 염증, 뇌부종, 인지 장애 등 장기적인 합병증으로 이어질 수 있습니다. 활성산소 제거 요법과 같은 접근법은 뇌 기능 개선에 유망하지만, BBB 손상의 변동성은 치료 전략을 복잡하게 만듭니다. TBI 치료 결과를 개선하기 위해서는 혁신적인 약물 전달 시스템과 BBB 온전성을 모니터링하는 더 나은 방법이 절실히 필요합니다. 이를 통해 더욱 효과적인 치료를 가능하게 하고 장기적인 신경학적 손상을 줄일 수 있습니다.
외상성 뇌 손상 치료 시장 범위
시장은 치료, 환자 연령, 성별, 부상 원인, 최종 사용자를 기준으로 세분화됩니다.
|
분할 |
하위 세분화 |
|
치료별 |
|
|
환자 연령별 |
|
|
성별에 따라 |
|
|
부상 원인에 따라 |
|
|
최종 사용자별 |
|
외상성 뇌 손상 치료 시장 지역 분석
“독일은 외상성 뇌 손상 치료 시장의 주요 국가입니다.”
- 독일은 첨단 의료 인프라와 의학 연구 개발에 대한 상당한 투자에 힘입어 유럽 외상성 뇌손상(TBI) 치료 시장을 선도할 것으로 예상됩니다.
- 이 나라는 뇌 손상 및 관련 질환에 초점을 맞춘 전문 신경과 병원, 재활 센터, 연구 기관으로 구성된 잘 정비된 네트워크를 자랑합니다.
- 또한 독일의 의료 정책은 조기 진단과 효과적인 치료 옵션을 보장하여 고품질 환자 치료를 지원하며, 이를 통해 TBI 치료 분야의 시장 리더로서의 입지를 더욱 강화합니다.
“ 독일이 가장 높은 성장률을 기록할 것으로 예상됩니다.”
- 독일은 TBI 관리 전략에 대한 인식 증가와 혁신적인 치료 방법 도입으로 인해 이 시장에서 가장 높은 연평균 성장률(CAGR)을 경험할 것으로 예상됩니다.
- 대중 인식 캠페인과 정부 이니셔티브의 확대로 외상성 뇌 손상에 대한 인식이 향상되어 더 빠른 개입과 더 나은 환자 결과가 나타났습니다.
- 또한 독일의 생명공학 및 제약 분야의 강력한 입지는 재생 치료 및 신경 보호 약물과 같은 최첨단 치료법 개발을 가속화하여 시장이 빠르게 성장하는 데 기여했습니다.
외상성 뇌 손상 치료 시장 점유율
시장 경쟁 구도는 경쟁사별 세부 정보를 제공합니다. 여기에는 회사 개요, 회사 재무 상태, 매출 창출, 시장 잠재력, 연구 개발 투자, 신규 시장 진출, 유럽 시장 진출, 생산 시설, 생산 능력, 회사의 강점과 약점, 제품 출시, 제품 종류 및 범위, 응용 분야별 우위 등이 포함됩니다. 위에 제공된 데이터는 해당 회사의 시장 집중도와 관련된 데이터입니다.
시장에서 활동하는 주요 시장 리더는 다음과 같습니다.
- 화이자(미국)
- 테바 파마슈티컬스 US, Inc. (미국)
- Fresenius SE & Co. KGaA(Fresenius Kabi AG)(독일)
- Viatris Inc. (미국)
- 암닐 파마슈티컬스 LLC. (미국)
- Dr. Reddy's Laboratories Ltd. (인도)
- Sun Pharmaceutical Industries, Inc.(인도)
- 루팡(인도)
- 히크마(요르단)
- Aurobindo Pharma US(인도)
- ICU 의료(미국)
- B. Braun Medical Inc. (독일)
- Alembic Pharmaceuticals Limited(인도)
- Merz Therapeutics(독일)
- Advacare(남아프리카공화국)
- 막지마(인도)
- Jedux Parenteral Private Limited(인도)
- Sagent Pharmaceuticals, Inc. (미국)
- 스위스 파마 나이지리아 리미티드(나이지리아)
외상성 뇌 손상 치료 시장의 최신 동향
- 2024년 2월, 비아트리스와 이도르시아는 다양한 치료 분야에 걸쳐 혁신적인 치료법 개발을 위한 북미 지역 주요 연구 개발 협력 계약을 체결했습니다. 이 파트너십은 이도르시아의 신약 개발 전문성과 비아트리스의 북미 시장 진출을 활용하여 획기적인 치료법 개발을 가속화하고 양사의 파이프라인을 확장하며, 전 세계적으로 충족되지 않은 의료 수요를 해결하려는 양사의 노력을 더욱 강화합니다.
- 2021년 2월, 프레제니우스 카비는 오스트리아 시설을 확장하여 제약 및 의료 기술 분야의 생산 역량과 혁신을 강화했습니다. 이번 확장을 통해 제조 효율성이 향상되고, 중환자 치료 제품의 안정적인 공급이 보장되며, 연구 발전이 촉진됩니다. 생산 능력 증대와 운영 효율성 향상을 통해 프레제니우스 카비는 시장 입지를 강화하고 북미 지역의 증가하는 의료 솔루션 수요를 충족할 수 있게 되었습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END-USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 TECHNOLOGY ROADMAP
4.4 VALUE CHAIN ANALYSIS
4.5 OPPUTUNITY MAP ANALYSIS
4.6 REIMBURSEMENT FRAMEWORK
4.7 COST ANALYSIS BREAKDOWN
4.8 PENETRATION AND GROWTH PROSPECT MAPPING: EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET
4.9 KEY PRICING STRATEGIES: EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET
4.1 MICRO AND MACRO-ECONOMIC FACTORS: EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET
5 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING INCIDENCE OF TRAUMATIC BRAIN INJURY (TBI)
6.1.2 GROWING ADOPTION OF MINIMALLY INVASIVE PROCEDURES IN TBI TREATMENT
6.1.3 TECHNOLOGICAL ADVANCEMENT FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURIES (TBI)
6.1.4 ADVANCEMENTS IN NEUROPROTECTION AND PHARMACOTHERAPY FOR TBI TREATMENT
6.2 RESTRAINTS
6.2.1 SHORTAGE OF TRAINED NEUROLOGISTS AND NEUROSURGEONS
6.2.2 HIGH COST OF TRAUMATIC BRAIN INJURY (TBI) TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING PERSONALIZED & TARGETED THERAPIES IN TRAUMATIC BRAIN INJURY (TBI)
6.3.2 GROWING BRAIN STIMULATION TECHNIQUES IN TRAUMATIC BRAIN INJURY (TBI) TREATMENT
6.3.3 RISING ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN DIAGNOSING TRAUMATIC BRAIN INJURY (TBI)
6.4 CHALLENGES
6.4.1 DIFFICULTIES IN OVERCOMING THE BLOOD-BRAIN BARRIER FOR TBI TREATMENT
6.4.2 ABSENCE OF STANDARDIZED TREATMENT PROTOCOLS IN TRAUMATIC BRAIN INJURY MANAGEMENT
7 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 SURGERY
7.2.1 BRAIN BLEEDING TREATMENT
7.2.2 REHABILITATION
7.2.3 CLOTTED BLOOD REMOVAL
7.2.4 WINDOW OPENING IN SKULL
7.2.5 REPAIRING SKULL FRACTURES
7.3 IMMEDIATE EMERGENCY CARE
7.4 MEDICATIONS
7.4.1 DIURETICS
7.4.2 ANTI-SEIZURE DRUGS (ANTI-CONVULSANT)
7.4.3 ANALGESIC
7.4.4 COMA-INDUCING DRUGS
7.4.5 ANTI-DEPRESSANTS
7.4.6 ANTI-ANXIETY AGENT
7.4.7 ANTI-PSYCHOTICS
7.4.8 ANTI-COAGULANTS
7.4.9 OTHERS
7.4.9.1 Parenteral
7.4.9.2 Oral
7.4.9.3 Others
8 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE
8.1 OVERVIEW
8.2 CHILDREN
8.3 TEENAGER
8.4 ELDER
9 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER
9.1 OVERVIEW
9.2 MALE
9.3 FEMALE
10 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, CAUSE OF INJURY
10.1 OVERVIEW
10.2 FALLS
10.3 MOTOR VEHICLE TRAFFIC
10.4 SPORTS
10.5 OTHERS
11 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 NEUROLOGY CLINICS
11.4 INDEPENDENT PHARMACIES
11.5 OTHERS
12 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION
12.1 EUROPE
12.1.1 GERMANY
12.1.2 U.K.
12.1.3 FRANCE
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 RUSSIA
12.1.7 NETHERLANDS
12.1.8 SWITZERLAND
12.1.9 TURKEY
12.1.10 BELGIUM
12.1.11 REST OF EUROPE
13 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 PFIZER INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT/NEWS
15.3 FRESENIUS SE & CO. KGAA (FRESENIUS KABI AG)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 VIATRIS INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 AMNEAL PHARMACEUTICALS LLC
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ADVACARE PHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 AUROBINDO PHARMA LIMITED
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ALEMBIC PHARMACEUTICALS LIMITED
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 B. BRAUN SE
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT UPDATES
15.1 DR. REDDY’S LABORATORIES LTD.
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PIPELINE PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 ICU MEDICAL, INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT/NEWS
15.12 HIKMA PHARMACEUTICALS PLC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PIPELINE PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 JEDUX PARENTERAL PRIVATE LIMITED
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 LUPIN
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 MERZ THERAPEUTICS
15.15.1 COMPANY SNAPSHOT
15.15.2 PIPELINE PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 MAXZIMAA
15.16.1 COMPANY SNAPSHOT
15.16.2 PIPELINE PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SWISS PHARMA NIGERIA LIMITED
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 SAGENT
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
표 목록
TABLE 1 NON-INVASIVE THERAPEUTIC APPROACHES’ EFFICIENCY IN DIFFERENT PHASES OF TBI
TABLE 2 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 3 EUROPE SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 4 EUROPE SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 EUROPE IMMEDIATE EMERGENCY CARE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 6 EUROPE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 EUROPE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 EUROPE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 9 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 10 EUROPE CHILDREN IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 EUROPE TEENAGER IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 EUROPE ELDER IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 14 EUROPE MALE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 EUROPE FEMALE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 17 EUROPE FALLS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 EUROPE MOTOR VEHICLE TRAFFIC IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 EUROPE SPORTS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 EUROPE OTHERS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 22 EUROPE HOSPITALS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 EUROPE NEUROLOGY CLINICS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 EUROPE INDEPENDENT PHARMACIES IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 EUROPE OTHERS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 27 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 28 EUROPE SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 EUROPE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 EUROPE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 31 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 32 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 33 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 34 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 35 GERMANY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 36 GERMANY SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 GERMANY MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 GERMANY MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 39 GERMANY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 40 GERMANY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 41 GERMANY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 42 GERMANY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 43 U.K. TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 U.K. SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 U.K. MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 U.K. MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 47 U.K. TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 48 U.K. TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 49 U.K. TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 50 U.K. TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 51 FRANCE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 FRANCE SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 FRANCE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 FRANCE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 55 FRANCE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 56 FRANCE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 57 FRANCE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 58 FRANCE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 59 ITALY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 60 ITALY SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 ITALY MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 ITALY MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 63 ITALY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 64 ITALY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 65 ITALY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 66 ITALY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 67 SPAIN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 68 SPAIN SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 SPAIN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 SPAIN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 71 SPAIN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 72 SPAIN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 73 SPAIN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 74 SPAIN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 75 RUSSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 76 RUSSIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 RUSSIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 RUSSIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 79 RUSSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 80 RUSSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 81 RUSSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 82 RUSSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 83 NETHERLANDS TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 84 NETHERLANDS SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 NETHERLANDS MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 NETHERLANDS MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 87 NETHERLANDS TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 88 NETHERLANDS TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 89 NETHERLANDS TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 90 NETHERLANDS TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 91 SWITZERLAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 92 SWITZERLAND SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 SWITZERLAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 SWITZERLAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 95 SWITZERLAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 96 SWITZERLAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 97 SWITZERLAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 98 SWITZERLAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 99 TURKEY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 100 TURKEY SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 TURKEY MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 TURKEY MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 103 TURKEY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 104 TURKEY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 105 TURKEY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 106 TURKEY TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 107 BELGIUM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 108 BELGIUM SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 BELGIUM MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 BELGIUM MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 111 BELGIUM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 112 BELGIUM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 113 BELGIUM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 114 BELGIUM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 115 REST OF EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: MARKET END-USER COVERAGE GRID
FIGURE 9 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING INCIDENCE OF TRAUMATIC BRAIN INJURY (TBI) IS EXPECTED TO DRIVE THE EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 SURGERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DROC ANALYSIS
FIGURE 16 TBI-RELATED DEATHS FROM 2018 TO 2024
FIGURE 17 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 18 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, 2025 TO 2032 (USD THOUSAND)
FIGURE 19 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, CAGR (2025- 2032)
FIGURE 20 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 21 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, 2024
FIGURE 22 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, 2025 TO 2032 (USD THOUSAND)
FIGURE 23 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, CAGR (2025- 2032)
FIGURE 24 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, LIFELINE CURVE
FIGURE 25 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, 2024
FIGURE 26 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 27 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER CAGR (2025-2032)
FIGURE 28 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 29 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, 2024
FIGURE 30 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, 2025-2032 (USD THOUSAND)
FIGURE 31 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, CAGR (2025-2032)
FIGURE 32 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, LIFELINE CURVE
FIGURE 33 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, 2024
FIGURE 34 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 35 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 36 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 38 EUROPE TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
